# Aaron S. Mansfield

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/aaron-s-mansfield/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,820 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 57 |
| i10-index | 170 |
| Last Known Institution | Mayo Clinic |
| OpenAlex ID | https://openalex.org/A5071440718 |
| ORCID iD | 0000-0002-9483-6903 |
| Works | 573 |

## Researcher papers

Showing 12 of 13.

- [First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung/)
- [Detection and localization of surgically resectable cancers with a multi-analyte blood test](https://scholariq.org/papers/detection-and-localization-of-surgically-resectable-cancers-with-a-multi-analyte/)
- [First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial](https://scholariq.org/papers/first-line-nivolumab-plus-ipilimumab-in-unresectable-malignant-pleural/)
- [Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)](https://scholariq.org/papers/updated-overall-survival-and-pd-l1-subgroup-analysis-of-patients-with-extensive/)
- [Integrating genomic features for non-invasive early lung cancer detection](https://scholariq.org/papers/integrating-genomic-features-for-non-invasive-early-lung-cancer-detection/)
- [Mesothelioma: Scientific clues for prevention, diagnosis, and therapy](https://scholariq.org/papers/mesothelioma-scientific-clues-for-prevention-diagnosis-and-therapy/)
- [Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study](https://scholariq.org/papers/pralsetinib-for-ret-fusion-positive-non-small-cell-lung-cancer-arrow-a-multi/)
- [Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years](https://scholariq.org/papers/representation-of-minorities-and-women-in-oncology-clinical-trials-review-of-the/)
- [PD-1 Restrains Radiotherapy-Induced Abscopal Effect](https://scholariq.org/papers/pd-1-restrains-radiotherapy-induced-abscopal-effect/)
- [Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions](https://scholariq.org/papers/amivantamab-plus-chemotherapy-in-nsclc-with-i-egfr-i-exon-20-insertions/)
- [First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743](https://scholariq.org/papers/first-line-nivolumab-plus-ipilimumab-versus-chemotherapy-in-patients-with/)
- [Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial](https://scholariq.org/papers/telisotuzumab-vedotin-monotherapy-in-patients-with-previously-treated-c-met/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Occupational and environmental lung diseases](https://scholariq.org/topics/occupational-and-environmental-lung-diseases/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Mayo Clinic](https://scholariq.org/institutions/mayo-clinic/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.